Corcept Therapeutics Incorporated
CORTHealthcareNASDAQBiotechnology · Last scanned May 28, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 27
Part of the healthcare sector, Corcept Therapeutics Incorporated (CORT) is listed under Biotechnology. The $7.15B market capitalization puts CORT squarely in mid-cap range for its industry. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Market Cap
$7.15B
Beta
0.35
P/E (TTM)
190.43
P/E (Fwd)
56.80
EPS (TTM)
$0.35
EPS (Fwd)
$1.17
ROE
7.2%
ROA
-0.6%
Cash
$338.2M
Total Debt
$9.6M
Free CF
$115.7M
52W Change
-14.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $338.2M in cash comfortably exceeding the $9.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $115.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 7.2%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $401.9M (2022) to $761.4M (2025), reflecting a 89% increase over the period.
CORT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CORT has financial flexibility that may help navigate uncertain periods. At over 50x earnings, CORT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Corcept Therapeutics Incorporated and its sector.